Pacritinib Citrate

CAS 937272-79-2

Interested in hearing more about this API?

Pacritinib is an azamacrocycle with formula C28H32N4O3. It is a Janus kinase inhibitor and its citrate salt is approved for the treatment of intermediate or high risk, primary or secondary myelofibrosis. It has a role as an EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor, an antineoplastic agent, an apoptosis inducer and an anti-inflammatory agent. It is an azamacrocycle, a member of pyrrolidines, a cyclic ether and a member of benzenes. It is a conjugate base of a pacritinib(1+).

About the API

Therapeutic category

Oncology

Regulations

US DMF

Systematic Name

(16E)-11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,27-triazatetracyclo[19.3.1.12,6.18,12]heptacosa-1(24),2(27),3,5,8(26),9,11,16,21(25),22-decaene

Molecular Formula

C28H32N4O3C28H32N4O3

Disclaimers:

This material might be protected by exclusive rights such as patents and/or supplementary protection certificates or extensions in certain jurisdictions, and therefore might not be available for specific countries. TAPI will only be able to offer and supply this pharmaceutical ingredient in the countries and exclusively for uses that are exempt from infringement of such exclusive rights in accordance with applicable law. TAPI requires adequate confirmation of the exempt use upon ordering.

The information detailed herein, including that with regard to active pharmaceutical ingredients , their use in treatments and possible mechanism(s) of action, was all obtained from public sources. For more information on our services and products – including product suitability, intended uses and current availability – please contact Teva api Customer Service. CAS Registry Number is a Registered Trademark of the American Chemical Society. This webpage and any reference to the above product is to be read within the meaning and terms of the Legal Notes.